BioAtla and GATC Health announced a $40 million SPV transaction to advance Ozuriftamab Vedotin (Oz-V).
BioAtla will receive $5 million initially for general operating and clinical trial expenses.
Remaining $35 million expected to close in Q1 2026 for Phase 3 trial execution of Oz-V in OPSCC.
Oz-V targets ROR2, a receptor linked to tumor progression and aging-related diseases.
Transaction Details
BioAtla receives $5 million initially and retains 65% ownership of Oz-V post-transaction.
Phase 3 Trial
BioAtla to lead Phase 3 trial for Oz-V in OPSCC with potential for accelerated approval.
Partnership Impact
Collaboration with Inversagen AI for research and development of senolytic therapies.
- Oz-V's targeting of ROR2 presents a promising approach for OPSCC treatment.
- Partnership enhances BioAtla's position in advancing cancer therapeutic applications.
- Potential for accelerated approval in the U.S. and expansion into HPV-positive solid tumors.
The SPV transaction signifies a significant step in advancing Oz-V towards Phase 3 development and potential approval, showcasing BioAtla's commitment to innovative cancer therapies.